LearnGlossaryMarketStocksSuperinvestorsSign in

TMDX

TransMedics Group, Inc.

Healthcare · $2.9B market cap

Verdict

We can't put a fair value on TMDX right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

3 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth393.3% a year✓
Equity per share growth30.0% a year✓
Sales growth84.6% a year✓
Free cash flow growth—?
Return on invested capital3.9%✗

Follow TMDX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds TMDX. In Q2 2026, 1 opened a position and 1 sold out. Who we track

Howard Marks

Oaktree Capital Management · as of Q2 2026

$3.4M

3,131,000 shares

Moves in Q2 2026

New position: Howard Marks

Sold out: Polen Capital Management

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works